Skip to main content
. 2019 Dec 16;29(12):1792–1803. doi: 10.1089/thy.2019.0328

Table 2.

Percentage of Papillae Within the Tumor, BRAF/NRAS Mutation, Nodal Metastasis, and Outcomes According to Invasion Status in Unifocal Encapsulated Papillary Thyroid Carcinoma

Cases with invasion (capsular and/or vascular)
  All patients (n = 79) N0/Nx (n = 64) N1 (n = 15) p-Values
Percentage of papillae
 0% 27 (34%) 27 (42%) 0 (0%) 0.001
 0.1–0.9% 11 (14%) 11 (17%) 0 (0%)
 1–9% 5 (6%) 4 (6%) 1 (7%)
 10–24% 3 (4%) 2 (3%) 1 (7%)
 25–49% 3 (4%) 3 (5%) 0 (0%)
 ≥50% 30 (38%) 17 (27%) 13 (87%)
BRAF/NRAS
 Positive BRAFV600E 13 (46%) 4 (24%) 9 (82%) 0.007
 Positive NRASQ61R 6 (21%) 6 (35%) 0 (0%)
 Negative 9 (32%) 7 (41%) 2 (18%)
Follow-up period, years, median (range) 6.7 (0.1–28.0) 6.8 (0.1–28.0) 5.5 (0.1–22.3) 0.491
Distant metastasis (n = 75)
 Absent 72 (96%) 58 (95%) 14 (100%) 0.451
 Present 3 (4%) 3 (5%) 0 (0%)
Noninvasive cases (capsular and/or vascular)
  All patients (n = 156) N0/Nx (n = 144) N1 (n = 12) p-Values
Percentage of papillae
 0%
 100 (64%)
 100 (69%)
 0 (0%)
 <0.001
 0.1–0.9%
 20 (13%)
 20 (14%)
 0 (0%)
 1–9%
 9 (6%)
 9 (6%)
 0 (0%)
 10–24%
 3 (2%)
 2 (1%)
 1 (8%)
 25–49%
 2 (1%)
 2 (1%)
 0 (0%)
 50%
 22 (14%)
 11 (8%)
 11 (92%)
BRAF/NRAS
 Positive BRAFV600E
 11 (15%)
 6 (9%)
 5 (62.5%)
 <0.001
 Positive NRASQ61R
 20 (28%)
 20 (31%)
 0 (0%)
 Negative
 41 (57%)
 38 (59%)
 3 (37.5%)
Follow-up period, years, median (range)
 5.2 (0.1–28.1)
 5.1 (0.1–28.1)
 6.5 (0.1–26.0)
 0.340
Distant metastasis (n = 144)
 Absent 144 (100%) 132 (100%) 12 (100%) NA

The BRAF and NRAS mutational status was determined by immunohistochemistry using monoclonal antibodies for BRAFV600E and NRASQ61R in a subset of 100 randomly selected cases. Significant p-values are highlighted in bold.